Tumor thrombus of inferior vena cava in patients with renal cell carcinoma – clinical and oncological outcome of 50 patients after surgery

BMC Research Notes

Hubertus Riedmiller¹  Martin Spahn¹  Arkadius Kocot¹  Andreas Loeser¹  Daniel Claudius Vergho¹ 

[1] Department of Urology, Julius Maximilian University Medical School, Oberduerrbacher Str. 6, D-97080, Würzburg, Germany

关键词: Tumor thrombus;    Thrombectomy;    Inferior vena cava;    Renal cell carcinoma;   

Others  :  1166378
DOI  :  10.1186/1756-0500-5-264

 received in 2011-11-10, accepted in 2012-06-01,  发布年份 2012

【 摘 要 】

Background

To evaluate oncological and clinical outcome in patients with renal cell carcinoma (RCC) and tumor thrombus involving inferior vena cava (IVC) treated with nephrectomy and thrombectomy.

Methods

We identified 50 patients with a median age of 65 years, who underwent radical surgical treatment for RCC and tumor thrombus of the IVC between 1997 and 2010. The charts were reviewed for pathological and surgical parameters, as well as complications and oncological outcome.

Results

The median follow-up was 26 months. In 21 patients (42%) distant metastases were already present at the time of surgery. All patients underwent radical nephrectomy, thrombectomy and lymph node dissection through a flank (15 patients/30%), thoracoabdominal (14 patients/28%) or midline abdominal approach (21 patients/42%), depending upon surgeon preference and upon the characteristics of tumor and associated thrombus. Extracorporal circulation with cardiopulmonary bypass (CPB) was performed in 10 patients (20%) with supradiaphragmal thrombus of IVC. Cancer-specific survival for the whole cohort at 5 years was 33.1%. Survival for the patients without distant metastasis at 5 years was 50.7%, whereas survival rate in the metastatic group at 5 years was 7.4%. Median survival of patients with metastatic disease was 16.4 months.

On multivariate analysis lymph node invasion, distant metastasis and grading were independent prognostic factors. There was no statistically significant influence of level of the tumor thrombus on survival rate. Indeed, patients with supradiaphragmal tumor thrombus (n = 10) even had a better outcome (overall survival at 5 years of 58.33%) than the entire cohort.

Conclusions

An aggressive surgical approach is the most effective therapeutic option in patients with RCC and any level of tumor thrombus and offers a reasonable longterm survival. Due to good clinical and oncological outcome we prefer the use of CPB with extracorporal circulation in patients with supradiaphragmal tumor thrombus. Cytoreductive surgery appears to be beneficial for patients with metastatic disease, especially when consecutive therapy is performed. Although sample size of our study cohort is limited consistent with some other studies lymph node invasion, distant metastasis and grading seem to have prognostic value.

【 授权许可】

   
2012 Vergho et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kirkali Z, Van Poppel H: A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol 2007, 52(3):658-662.
• [2]Kaag MG, Toyen C, Russo P, Cronin A, Thompson RH, Schiff J, Bernstein M, Bains M: Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU Int 2011, 107(9):1386-1393.
• [3]Haferkamp A, Bastian PJ, Jakobi H, Pritsch M, Pfitzenmaier J, Albers P, Hallscheidt P, Mueller S, Hohenfellner M: Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol 2007, 177(5):1703-1708.
• [4]Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, DeKernion JB, Figlin RA, Belldegrun AS: Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003, 169(3):909-916.
• [5]Ciancio G, Livingstone AS, Soloway M: Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: the University of Miami experience in using liver transplantation techniques. Eur Urol 2007, 51(4):988-994.
• [6]Staehler G, Brkovic D: The role of radical surgery for renal cell carcinoma with extension into the vena cava. J Urol 2000, 163(6):1671-1675.
• [7]Tanaka M, Fujimoto K, Okajima E, Tanaka N, Yoshida K, Hirao Y: Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol 2008, 15(5):394-398.
• [8]Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY: The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011, 185(1):60-66.
• [9]You D, Jeong IG, Ahn JH, Lee DH, Lee JL, Hong JH, Ahn H, Kim CS: The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol 2011, 185(1):54-59.
• [10]Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Frank I, Thompson RH, Blute ML: Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol 2005, 173(3):716-719.
• [11]Belis JA, Kandzari SJ: Five-year survival following excision of renal cell carcinoma extending into inferior vena cava. Urology 1990, 35(3):228-230.
• [12]Moinzadeh A, Libertino JA: Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004, 171(2pt1):598-601.
• [13]Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6(7):655-663.
• [14]Neves RJ, Zincke H: Surgical treatment of renal cancer with vena cava extension. Br J Urol 1987, 59(5):390-395.
• [15]Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004, 240(2):205-213.
• [16]Ciancio G, Manoharan M, Katkoori D, De Los SR, Soloway MS: Long-term Survival in Patients Undergoing Radical Nephrectomy and Inferior Vena Cava Thrombectomy: Single-Center Experience. Eur Urol 2010, 57(4):667-671.
• [17]Libertino JA, Zinman L, Watkins E: Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Uro 1987, 137(1):21-24.
• [18]Swierzewski DJ, Swierzewski MJ, Libertino JA: Radical nephrectomy in patients with renal cell carcinoma with venous, vena caval, and atrial extension. Am J Surg 1994, 168(2):205-209.
• [19]Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM: Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology 2007, 69(6):1054-1058.
• [20]Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171(3):1071-1076.
• [21]Mickisch GH, Garin A, Van Poppel H, De Prick L, Sylvester R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358(9286):966-970.
• [22]Di Lorenzo G, Autorino R, Sternberg CN: Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. Eur Urol 2009, 56(6):959-971.
• [23]Di Silverio F, Sciarra A, Parente U, Andrea A, Von Heland M, Panebianco V, Passariello R: Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008, 80(4):451-453.
• [24]Wagner B, Patard JJ, Mejean A, Bensalah K, Verhoest G, Zigeuner R, Ficarra V, Tostain J, Mulders P, Chautard D, Descotes J, Taille A, Salomon L, Prayer-Galetti T, Cindolo L, Valeri A, Meyer N, Jacqmin D, Lang H: Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma. Eur Urol 2009, 55(2):452-459.
• [25]Martinez-Salamanca JI, Huang WC, Millan I, Bertini R, Bianco FJ, Carballido JA, Cianco G, Hernandez C, Herranz F, Haferkamp A, Hohenfellner M, Hu B, Koppie T, Martinez-Ballesteros C, Montorsi F, Palou J, Pontes JE, Russo P, Terrone C, Villavicencio H, Volpe A, Libertino JA: Prognostic Impact of the 2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma with Venous Extension. Eur Urol 2011, 59:120-127.
• [26]Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS: Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 2007, 178(4pt1):1189-1195.
• [27]Ljungberg B, Stenling R, Osterdahl B, Farrelly E, Aberg T, Roos G: Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. J Urol 1995, 154(5):1681-1684.
• [28]Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincker H: The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004, 94(1):33-41.
• [29]Novick AC, Kaye MC, Cosgrove DM, Angermeier K, Pontes JE, Montie JE, Streem SB, Klein E, Stewart R, Goormastic M: Experience with cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of retroperitoneal tumors with large vena caval thrombi. Ann Surg 1990, 212(4):472-476.
• [30]Stewart JR, Carey JA, McDougal WS, Merrill WH, Koch MO, Bender HW: Cavoatrial tumor thrombectomy using cardiopulmonary bypass without circulatory arrest. Ann Thorac Surg 1991, 51(5):717-721.
• [31]Granberg CF, Boorjian SA, Schaff HV, Orszulak TA, Leibovich BC, Lohse CM, Cheville JC, Blute ML: Surgical Management, Complications, and Outcome of Radical Nephrectomy with Inferior Vena Cava Tumor Thrombectomy Facilitated by Vascular Bypass. Urology 2008, 73(1):148-152.